Surveillance IDs New Tumors in Children With Cancer Predisposition
21 Jun 2024
ASCOClinical Result
FRIDAY, June 21, 2024 -- Standardized surveillance identifies new tumors among children with a wide spectrum of cancer predisposition syndromes (CPSs), according to a study published online June 20 in JAMA Oncology.
Alise Blake, from St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues reviewed surveillance outcomes for children and young adults from birth to age 23 years with a clinical and/or molecular CPS diagnosis. A total of 274 children and young adults with 35 CPSs were monitored using standard surveillance regimens for their CPS at a specialty pediatric oncology center.
The researchers found that 35 asymptomatic tumors were detected in 27 patients (9.9 percent of the cohort) through surveillance during the study period and five symptomatic tumors were detected in five patients (1.8 percent of the cohort) outside surveillance, two of whom also had tumors detected through surveillance. Of the 35 tumors, 10 (28.6 percent) were identified on first surveillance imaging. Malignant solid and brain tumors identified through surveillance were more often localized than similar tumors detected before diagnosis of CPS (20 of 24 versus 71 of 125 [83.3 versus 56.8 percent]). Completely negative margins were obtained in 17 of the 24 tumors identified through surveillance and surgically resected. High sensitivity, specificity, positive predictive value, and negative predictive value were seen across imaging modalities (96.4, 99.6, 94.3, and 99.6 percent, respectively); there were few false-positive or false-negative findings (0.4 and 0.3 percent, respectively).
"Standardized surveillance successfully uncovers new asymptomatic tumors in children and young adults across a broad range of CPSs," the authors write.
One author disclosed ties to Alexion.
Abstract/Full Text
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.